Recruiting Phase 2 2024-519799-25-00

efficacy and safety of the use of regulatory T cells in immune hyperactivation in patients with COVID-19 and/or acute respiratory distress syndrome

Phase 2 – studying effectiveness and dosage

Conditions: immune hyperactivation in COVID-19 patients and/or acute respiratory distress syndrome

Sponsor: Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon

trial.available_in:

БГ

Overview

Trial status: Authorised

Who can participate

Age group: 18-64 years Gender: Female, Male Target enrollment: 24 participants

Spain (1)

Status

Recruiting

Phase

Phase 2

Study type

INTERVENTIONAL

Sex

Male and female

Minimum age

18 Years

Maximum age

64 Years

Healthy volunteers

Start date

30.01.2025

Registry ID

2024-519799-25-00

Source

euclinicaltrials.eu

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.